Latest period
$8.75B
YoY change
-4.5%
5Y CAGR
+19.1%
Peak year (2023)
$10.84B
Latest annual
$8.61B
Cash on Hand history chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
Latest: $8.61B
Cash on Hand growth chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
Latest: -4.5%
Cash on Hand history table for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
| 2025 | $8.61B | -4.5% | −$407.30M | ||
| 2024 | $9.01B | -16.9% | −$1.83B | ||
| 2023 | $10.84B | +40.1% | +$3.10B | ||
| 2022 | $7.74B | +36.0% | +$2.05B | ||
| 2021 | $5.69B | +58.8% | +$2.11B | ||
| 2020 | $3.59B | +11.6% | +$372.70M | ||
| 2019 | $3.21B | +14.4% | +$404.40M | ||
| 2018 | $2.81B | +99.4% | +$1.40B | ||
| 2017 | $1.41B | +35.7% | +$370.82M | ||
| 2016 | $1.04B | -0.6% | −$6.54M | ||
| 2015 | $1.05B | +16.1% | +$144.74M | ||
| 2014 | $900.48M | +29.8% | +$206.50M | ||
| 2013 | $693.98M | +125.3% | +$385.89M | ||
| 2012 | $308.10M | -41.5% | −$218.85M | ||
| 2011 | $526.94M | +111.3% | +$277.57M | ||
| 2010 | $249.37M | -26.9% | −$91.96M | ||
| 2009 | $341.33M | -28.1% | −$133.42M | ||
| 2008 | $474.75M | -38.1% | −$291.71M | ||
| 2007 | $766.46M | +66.9% | +$307.18M | ||
| 2006 | $459.28M | +53.8% | +$160.73M | ||
| 2005 | $298.55M | +0.9% | +$2.56M | ||
| 2004 | $295.98M | +0.8% | +$2.21M | ||
| 2003 | $293.77M | +11.2% | +$29.50M | ||
| 2002 | $264.27M | -31.4% | −$120.81M | ||
| 2001 | $385.08M | +227.4% | +$267.47M | ||
| 2000 | $117.61M | +77.7% | +$51.41M | ||
| 1999 | $66.20M | +234.3% | +$46.40M | ||
| 1998 | $19.80M | -31.5% | −$9.10M | ||
| 1997 | $28.90M | -16.2% | −$5.60M | ||
| 1996 | $34.50M | +5.5% | +$1.80M | ||
| 1995 | $32.70M | +38.6% | +$9.10M | ||
| 1994 | $23.60M | +88.8% | +$11.10M | ||
| 1993 | $12.50M | -23.8% | −$3.90M | ||
| 1992 | $16.40M | -37.4% | −$9.80M | ||
| 1991 | $26.20M | +20.2% | +$4.40M | ||
| 1990 | $21.80M | — | — |
- 2025$8.61B-4.5%
- 2024$9.01B-16.9%
- 2023$10.84B+40.1%
- 2022$7.74B+36.0%
- 2021$5.69B+58.8%
- 2020$3.59B+11.6%
- 2019$3.21B+14.4%
- 2018$2.81B+99.4%
- 2017$1.41B+35.7%
- 2016$1.04B-0.6%
- 2015$1.05B+16.1%
- 2014$900.48M+29.8%
- 2013$693.98M+125.3%
- 2012$308.10M-41.5%
- 2011$526.94M+111.3%
- 2010$249.37M-26.9%
- 2009$341.33M-28.1%
- 2008$474.75M-38.1%
- 2007$766.46M+66.9%
- 2006$459.28M+53.8%
- 2005$298.55M+0.9%
- 2004$295.98M+0.8%
- 2003$293.77M+11.2%
- 2002$264.27M-31.4%
- 2001$385.08M+227.4%
- 2000$117.61M+77.7%
- 1999$66.20M+234.3%
- 1998$19.80M-31.5%
- 1997$28.90M-16.2%
- 1996$34.50M+5.5%
- 1995$32.70M+38.6%
- 1994$23.60M+88.8%
- 1993$12.50M-23.8%
- 1992$16.40M-37.4%
- 1991$26.20M+20.2%
- 1990$21.80M—
Cash on Hand values are taken from Regeneron Pharmaceuticals's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Cash on Hand at Regeneron Pharmaceuticals (REGN)
According to Regeneron Pharmaceuticals's latest reported financial statements, the company's latest reported cash and short-term investments is $8.75B. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for net leverage and total assets for the share of assets held in cash.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Regeneron Pharmaceuticals (REGN) reported cash and short-term investments of $8.61B – edged down 4.5% year-over-year.
Regeneron Pharmaceuticals cash and short-term investments compound annual growth for the 2020–2025 (5 years) window is +19.1%, with mixed annual results across the window.
Regeneron Pharmaceuticals cash and short-term investments peaked at $10.84B in 2023; the latest annual figure is $8.61B in 2025 (20.7% below peak).
$10.84B stands as the all-time-high annual cash and short-term investments, posted in 2023, against a low of $12.50M during 1993.
Regeneron Pharmaceuticals Cash on Hand by Year
Regeneron Pharmaceuticals Cash on Hand 2025: $8.61B
In 2025, Regeneron Pharmaceuticals reported cash and short-term investments of $8.61B, edged down 4.5% below 2024.
Regeneron Pharmaceuticals Cash on Hand 2024: $9.01B
Regeneron Pharmaceuticals cash and short-term investments in 2024 was $9.01B, declined 16.9% below 2023.
Regeneron Pharmaceuticals Cash on Hand 2023: $10.84B
2023's cash and short-term investments for Regeneron Pharmaceuticals came in at $10.84B, surged 40.1% from 2022. This figure represents the highest annual value in the available history.
Regeneron Pharmaceuticals Cash on Hand 2022: $7.74B
Regeneron Pharmaceuticals posted cash and short-term investments of $7.74B in 2022, surged 36.0% from 2021.
Regeneron Pharmaceuticals Cash on Hand 2021: $5.69B
Regeneron Pharmaceuticals cash and short-term investments in 2021 was $5.69B.
See more financial history for Regeneron Pharmaceuticals (REGN).
Sector peers by Cash on Hand
Healthcare peers of Regeneron Pharmaceuticals (REGN), ranked by their latest cash and short-term investments
| $28.12B | |
| $20.10B | |
| $14.56B | |
| $9.13B | |
| $7.27B | |
| $5.74B | |
| $5.26B | |
| $4.24B |
- $28.12B
- $20.10B
- $14.56B
- $9.13B
- $7.27B
- $5.74B
- $5.26B
- $4.24B
Frequently asked questions
Regeneron Pharmaceuticals (REGN) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation